Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 400 Atlantic Street, Suite 500 STAMFORD CT 06901 |
Tel: | N/A |
Website: | https://www.caratherapeutics.com |
IR: | See website |
Key People | ||
Christopher A. Posner President, Chief Executive Officer, Director | Ryan D. Maynard Chief Financial Officer | Frederique Menzaghi Senior Vice President - Research and Development, Chief Scientific Officer |
Scott M. Terrillion Chief Compliance Officer, General Counsel, Secretary | Joana Goncalves Chief Medical Officer |
Business Overview |
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide. |
Financial Overview |
For the fiscal year ended 31 December 2023, Cara Therapeutics Inc revenues decreased 50% to $21M. Net loss increased 39% to $118.5M. Revenues reflect License and milestone fees decrease of 94% to $910K, Commercial supply revenue decrease of 43% to $5.8M, Collaborative revenue decrease of 22% to $12.9M. Higher net loss reflects Research and development - Balancing increase of 21% to $100.3M (expense). |
Employees: | 55 as of Mar 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $20.97M as of Dec 31, 2023 |
EBITDA (TTM): | -$121.24M as of Dec 31, 2023 |
Net annual income (TTM): | -$118.51M as of Dec 31, 2023 |
Free cash flow (TTM): | -$94.45M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 54,656,413 as of Mar 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |